About Hexagon Bio
Hexagon Bio is a Healthcare company based in Menlo Park (United States) founded in 2017. Bioinformatics tools are provided for analyzing microbial genomic sequencing data. Hexagon Bio has raised $205.6 million across 5 funding rounds from investors including CPP Investments, SoftBank Vision Fund and The Column Group. The company has 34 employees. Its Indian entity Hexagon Bio Organics Private Limited reported revenue of ₹3.81 Cr. Hexagon Bio offers products and services including Science Platform and Antibody Drug Conjugates. Its focus areas include Life Sciences, Genomics, Genomics Services and Bioinformatics. Its competitors include Seven Bridges Genomics, Ingenuity Systems and Tessera Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Hexagon Bio was founded in 2017 and is based in Menlo Park, United States. Operations focus on the bioinformatics sector, where tools are developed for processing microbial genome sequencing data. Researchers utilize the platform to examine sequencing outputs and pinpoint small-molecule drug candidates for therapeutic uses across various applications. Services emphasize data analysis support in biotechnology and pharmaceuticals.
- Headquarters Menlo Park, United States
- Employees 34
- SectorsHealthcare
- Email••••••••
- Website hexagonbio.com
- Social LinkedIn X
- Legal Name Hexagon Bio, Inc.
- Date of Incorporation 18 May, 2012
- Indian entity revenue₹3.81 Cr
FY 2024 · -36% YoY
- Indian entity net profit₹2.8 Lakh
FY 2024 · 1% margin
- Indian entity EBITDA₹4.6 Lakh
FY 2024 · 1% margin
- Total Equity Funding$205.6M (USD)
in 5 rounds
- Latest Funding Round$77.3M (USD), Series B
Sep 2022
- InvestorsCPP Investments
& 6 more
- Employee Count34
Associated legal entities of Hexagon Bio
Hexagon Bio operates through Hexagon Bio Organics Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Hexagon Bio Organics Private Limited CIN U24120TG2012PTC081038 | Active | 18 May 2012 | Hyderabad, Telangana | ₹3.8 Cr | 2 | View details |
Products & Services of Hexagon Bio
Hexagon Bio offers a comprehensive portfolio of products and services, including Science Platform and Antibody Drug Conjugates.
Platform for mining genomes and developing novel ADC payloads using computation.
Solutions for creating next-generation cancer treatments with orthogonal mechanisms.
Funding Insights of Hexagon Bio
Hexagon Bio has successfully raised a total of $205.6M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $77.3 million completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $205.6M
- Total Rounds 5
- Last Round Series B — $77.3M
- First Round $8.3M
(Jun 2017)
- Investors Count 7
All 5 funding rounds of Hexagon Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2022 | $77.3M | Series B | – | – | |
| Jun 2021 | $61M | Series B | – | Nextech Invest | |
| Sep 2020 | $47M | Series A | – | TCG, Two Sigma Ventures | – |
| Apr 2018 | $12M | Series A | – | – | – |
| Jun 2017 | $8.3M | Series A | – | – | – |
7 investors in total: 7 institutional.
Investors in Hexagon Bio
Hexagon Bio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include CPP Investments, SoftBank Vision Fund and The Column Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage investments in US life science startups are focused on. | 2007 | thecolumngroup.com | San Francisco, United States | |
Early-stage investments in tech sectors are managed by the firm. | twosigmaventures.com | New York, United States | ||
Venture capital firm investing in technology, life sciences, and related sectors. | 8vc.com | |||
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland | ||
Venture capital investments in technology and startups. | 2016 | visionfund.com | London, United Kingdom | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Pension fund assets are managed for sustainable long-term growth. | 1997 | cppinvestments.com | Toronto, Canada |
Investor details for Hexagon Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Hexagon Bio Organics Private Limited (Hexagon Bio)
Hexagon Bio Organics Private Limited is the primary company behind Hexagon Bio. The board of Hexagon Bio Organics Private Limited currently have 2 directors; the longest-serving is Reshma Begum, appointed in 2012.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Reshma Begum DIN 05224641 | Director | 18 May 2012 | 14 yrs 5 mo | Hexagon Bio Organics Private Limited |
| Mohammed Abdul Hakeem DIN 05224649 | Director | 18 May 2012 | 14 yrs 5 mo | Hexagon Bio Organics Private Limited |
People of Hexagon Bio
40 people are tracked at Hexagon Bio (11 in leadership, 12 in board & advisors, 17 in team); the tracked headcount is 34.
| Name | Role | Group |
|---|---|---|
Natacha Le Moan | VP, Biology | Leadership |
Maureen Hillenmeyer | CEO & Founder | Leadership |
Corey Reeves | Senior Director, Head of Medicinal Chemistry | Leadership |
Andy Aymeloglu | Head of Engineering | Leadership |
Georgia Campbell | Head Of Operations | Leadership |
Tara Arvedson | Chief Scientific Officer | Leadership |
Phoebe Leong | Senior Director, Lab Operations | Leadership |
Kunal Patel | Svp, Head Of Business Development | Leadership |
Amandeep Gakhal | Senior Director - ADC & Cell Biology, Late Discovery | Leadership |
Joe Spraker | Director - Fungal Genetics/sequence The Earth | Leadership |
J. Colin Cox | Senior Director Of Automation | Leadership |
David Goeddel | Director | Board & advisors |
Alex Kolicich | Director | Board & advisors |
Juan Jaen | Director | Board & advisors |
Millie Ray | Director | Board & advisors |
Eva Nogales | Advisor | Board & advisors |
Steven McKnight | Advisor | Board & advisors |
John Josey | Advisor | Board & advisors |
Davide Ruggero | Advisor | Board & advisors |
Frank C. Schroeder | Advisor | Board & advisors |
20 more people are available in the full profile.
Complete people profiles for Hexagon Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Hexagon Bio
Figures of Hexagon Bio Organics Private Limited, the primary company behind Hexagon Bio, for FY 2024. Revenue was ₹3.81 Cr (-36% year on year). Net profit was ₹2.8 Lakh (1% margin). EBITDA was ₹4.6 Lakh (1% margin). Revenue has grown at a compounded annual rate of -16% over three years and +13% over five years.
- ₹3.81 CrRevenue · FY 2024 · -36% YoY
- ₹2.8 LakhNet profit · 1% margin
- ₹4.6 LakhEBITDA · 1% margin
- ₹1 LakhPaid-up capital
- -16%Revenue CAGR, 3 years
- +13%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Hexagon Bio Organics Private Limited are on its company page.
Detailed financial statements for Hexagon Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Hexagon Bio
3 dated milestones of Hexagon Bio across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Hexagon Bio is founded.
- Funding First funding round of $8.3M.
- Funding Latest funding round, Series B, of $77.3M.
Competitors of Hexagon Bio
Hexagon Bio has 3 listed competitors in our database, 3 of them funded. They include Seven Bridges Genomics, Ingenuity Systems and Tessera Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sevenbridges.com | 2009 | Cambridge, United States | $113M | 112 | Cloud-based platform to analyze, store, and act on genomic data. | |
| ingenuity.com | 1998 | Redwood, United States | $20.4M | 30 | Genomic data is analyzed and interpreted via web-based applications. | |
| tesseratherapeutics.com | 2017 | Cambridge, United States | $610M | 149 | New genome engineering technology is provided for treating multiple diseases. |
Detailed competitors of Hexagon Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Hexagon Bio
The website of Hexagon Bio (hexagonbio.com) receives about 5.6K visits a month.
- Monthly visits5.6K
▲ 31.8% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Hexagon Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hexagon Bio
Complete news archive for Hexagon Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hexagon Bio
Hexagon Bio was founded in 2017.
Hexagon Bio is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Hexagon Bio is a funded company, having raised a total of $205.6M across 5 funding rounds to date. The company's 1st funding round was a Series A of $8.3M, raised on Jun 2017.
Hexagon Bio has 34 employees.
The primary company behind Hexagon Bio, Hexagon Bio Organics Private Limited, reported revenue of ₹3.81 Cr for FY 2024, down 36% year on year.
Hexagon Bio was founded in 2017 and is based in Menlo Park, United States. Operations focus on the bioinformatics sector, where tools are developed for processing microbial genome sequencing data. Researchers utilize the platform to examine sequencing outputs and pinpoint small-molecule drug candidates for therapeutic uses across various applications. Services emphasize data analysis support in biotechnology and pharmaceuticals.
Hexagon Bio's top competitors include Tessera Therapeutics, Ingenuity Systems and Seven Bridges Genomics.
Hexagon Bio offers Science Platform and Antibody Drug Conjugates.
Hexagon Bio has 7 investors. Key investors include CPP Investments, SoftBank Vision Fund, The Column Group, Two Sigma Ventures, and 8VC.
Hexagon Bio operates through Hexagon Bio Organics Private Limited.
The legal entities of Hexagon Bio currently have 2 directors, including Reshma Begum, Mohammed Abdul Hakeem.